Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022)

Prime Medicine filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $395.8 million for Q3 2022.

  • On a quarterly basis, Preferred Stock Liabilities rose 101.78% to $395.8 million in Q3 2022 year-over-year; TTM through Sep 2022 was $395.8 million, a 101.78% increase, with the full-year FY2021 number at $395.8 million, changed N/A from a year prior.
  • Preferred Stock Liabilities hit $395.8 million in Q3 2022 for Prime Medicine, up from $199.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $395.8 million in Q4 2021 to a low of $196.2 million in Q3 2021.